PMID- 35316483
OWN - NLM
STAT- MEDLINE
DCOM- 20220914
LR  - 20220915
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 22
IP  - 5
DP  - 2022 Sep
TI  - Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based 
      Clinical Approach.
PG  - 463-474
LID - 10.1007/s40256-022-00531-y [doi]
AB  - Antithrombotic therapy is the cornerstone of pharmacological treatment in 
      patients undergoing primary percutaneous coronary intervention (PCI). However, 
      the acute management of ST elevation myocardial infarction (STEMI) patients 
      includes therapy for pain relief and potential additional strategies for 
      cardioprotection. The safety and efficacy of some commonly used treatments have 
      been questioned by recent evidence. Indeed a concern about morphine use is the 
      interaction between opioids and oral P2Y(12) inhibitors; early beta-blocker 
      treatment has shown conflicting results for the improvement of clinical outcomes; 
      and supplemental oxygen therapy lacks benefit in patients without hypoxia and may 
      be of potential harm. Other additional strategies remain disappointing; however, 
      some treatments may be selectively used. Therefore, we intend to present a 
      critical updated review of complementary pharmacotherapy for a modern treatment 
      approach for STEMI patients undergoing primary PCI.
CI  - (c) 2022. The Author(s).
FAU - Fabris, Enrico
AU  - Fabris E
AUID- ORCID: 0000-0001-9458-0736
AD  - Cardiovascular Department, University of Trieste, Trieste, Italy.
FAU - Selvarajah, Abi
AU  - Selvarajah A
AD  - Department of Cardiology, Isala Heart Centre, Zwolle, The Netherlands.
FAU - Tavenier, Annerieke
AU  - Tavenier A
AD  - Department of Cardiology, Isala Heart Centre, Zwolle, The Netherlands.
FAU - Hermanides, Rik
AU  - Hermanides R
AD  - Department of Cardiology, Isala Heart Centre, Zwolle, The Netherlands.
FAU - Kedhi, Elvin
AU  - Kedhi E
AD  - Erasmus Hospital, Universite libre de Bruxelles (ULB), Brussels, Belgium.
AD  - Silezian Medical University, Katowice, Poland.
FAU - Sinagra, Gianfranco
AU  - Sinagra G
AD  - Cardiovascular Department, University of Trieste, Trieste, Italy.
FAU - Van't Hof, Arnoud
AU  - Van't Hof A
AD  - Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands. 
      arnoud.vant.hof@mumc.nl.
AD  - Department of Cardiology, Maastricht University Medical, Maastricht, The 
      Netherlands. arnoud.vant.hof@mumc.nl.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The 
      Netherlands. arnoud.vant.hof@mumc.nl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220322
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *ST Elevation Myocardial Infarction/drug therapy/etiology
MH  - Treatment Outcome
PMC - PMC9468081
COIS- Dr. E. Kedhi reports personal fees from Abbott and personal fees from Medtronic, 
      outside this submitted work; Dr. A. van't Hof reports grants from Medtronic, 
      Abbott, Boehringer Ingelheim, and AstraZeneca, all outside this submitted work; 
      Dr. E. Fabris, A. Selvarajah, A. Tavenier, R. Hermanides, and G. Sinagra have 
      declared no potential conflicts of interest that might be relevant to this work.
EDAT- 2022/03/23 06:00
MHDA- 2022/09/15 06:00
PMCR- 2022/03/22
CRDT- 2022/03/22 17:18
PHST- 2022/02/24 00:00 [accepted]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/09/15 06:00 [medline]
PHST- 2022/03/22 17:18 [entrez]
PHST- 2022/03/22 00:00 [pmc-release]
AID - 10.1007/s40256-022-00531-y [pii]
AID - 531 [pii]
AID - 10.1007/s40256-022-00531-y [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2022 Sep;22(5):463-474. doi: 10.1007/s40256-022-00531-y. 
      Epub 2022 Mar 22.